Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00482014 · ClinicalTrials.gov registry record · Phase 1
A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
NCT00482014 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 120 participants.
The verdict
NCT00482014, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine the 2-year survival rate of both of the chemotherapy regimens in patients with inoperable non-small-cell lung cancer.
Interventions
- DRUG cisplatin
- DRUG carboplatin
- DRUG pemetrexed
- RADIATION radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2007-05 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00482014
The ClinicalTrials.gov registry entry for NCT00482014 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which cisplatin is the first listed.
NCT00482014 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00482014 about?
NCT00482014 is a clinical study titled "A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer". The primary purpose of this study is to determine the 2-year survival rate of both of the chemotherapy regimens in patients with inoperable non-small-cell lung cancer.
What is the current status of trial NCT00482014?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2007-05. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00482014?
The interventions under investigation include: cisplatin (DRUG), carboplatin (DRUG), pemetrexed (DRUG), radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT00482014?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.